CN118974082A - 通过使用抗c5抗体可伐利单抗用于治疗或预防格林-巴利综合征的剂量及施用方案 - Google Patents

通过使用抗c5抗体可伐利单抗用于治疗或预防格林-巴利综合征的剂量及施用方案 Download PDF

Info

Publication number
CN118974082A
CN118974082A CN202380031438.3A CN202380031438A CN118974082A CN 118974082 A CN118974082 A CN 118974082A CN 202380031438 A CN202380031438 A CN 202380031438A CN 118974082 A CN118974082 A CN 118974082A
Authority
CN
China
Prior art keywords
antibody
subject
ivig
dose
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202380031438.3A
Other languages
English (en)
Chinese (zh)
Inventor
S·B·M·布阿托斯
五反田圭介
四宫贤治
A·A·B·索斯特利
A·P·M·苏布雷特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Chugai Pharmaceutical Co Ltd
Original Assignee
F Hoffmann La Roche AG
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG, Chugai Pharmaceutical Co Ltd filed Critical F Hoffmann La Roche AG
Publication of CN118974082A publication Critical patent/CN118974082A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN202380031438.3A 2022-04-04 2023-04-03 通过使用抗c5抗体可伐利单抗用于治疗或预防格林-巴利综合征的剂量及施用方案 Pending CN118974082A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP22166585.4 2022-04-04
EP22166585 2022-04-04
PCT/EP2023/058608 WO2023194273A1 (en) 2022-04-04 2023-04-03 Dosage and administration regimen for the treatment or prevention of guillan-barré syndrome by the use of the anti-c5 antibody crovalimab

Publications (1)

Publication Number Publication Date
CN118974082A true CN118974082A (zh) 2024-11-15

Family

ID=81327202

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202380031438.3A Pending CN118974082A (zh) 2022-04-04 2023-04-03 通过使用抗c5抗体可伐利单抗用于治疗或预防格林-巴利综合征的剂量及施用方案

Country Status (11)

Country Link
US (1) US20250236662A1 (https=)
EP (1) EP4504774A1 (https=)
JP (1) JP2025511382A (https=)
KR (1) KR20240168984A (https=)
CN (1) CN118974082A (https=)
AU (1) AU2023249891A1 (https=)
CA (1) CA3251880A1 (https=)
IL (1) IL314751A (https=)
MX (1) MX2024012073A (https=)
TW (1) TW202404632A (https=)
WO (1) WO2023194273A1 (https=)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9388235B2 (en) * 2006-09-05 2016-07-12 Alexion Pharmaceuticals, Inc. Methods and compositions for the treatment of antibody mediated neuropathies
BR112017011235A2 (pt) 2014-12-19 2018-02-06 Chugai Pharmaceutical Co Ltd anticorpos anti-c5 e métodos de uso
DK3658184T5 (da) * 2017-07-27 2024-08-26 Alexion Pharma Inc Højkoncentrerede anti-c5-antistofformuleringer
CR20220040A (es) * 2019-07-31 2022-03-02 Hoffmann La Roche Régimen de dosificación y administración para el tratamiento o prevención de enfermedades relacionadas con c5 mediante el uso del anticuerpo anti-c5 crovalimab

Also Published As

Publication number Publication date
MX2024012073A (es) 2024-11-08
WO2023194273A1 (en) 2023-10-12
US20250236662A1 (en) 2025-07-24
EP4504774A1 (en) 2025-02-12
CA3251880A1 (en) 2023-10-12
AU2023249891A1 (en) 2024-08-08
AU2023249891A9 (en) 2024-08-15
JP2025511382A (ja) 2025-04-15
TW202404632A (zh) 2024-02-01
KR20240168984A (ko) 2024-12-02
IL314751A (en) 2024-10-01

Similar Documents

Publication Publication Date Title
JP2022525164A5 (https=)
US20250075007A1 (en) Treatment of Al Amyloidosis with the Combination of Monoclonal Antibodies Agains Immunoglobulin Light Chains and the CD38 Cell Membrane Molecule on Antibody-Producing And Other Immune Cells
US20220127346A1 (en) Methods of Safe Administration of Anti-Tau Antibody
JP2023548005A (ja) 抗トランスサイレチン抗体およびその使用方法
WO2019186369A1 (en) Methods of treating chronic spontaneous urticaria using ligelizumab
US20220356261A1 (en) Treatment for sjögren's syndrome
US20220127345A1 (en) Methods of Reducing Tau in Human Subjects
TW202321303A (zh) 抗pla2r自體抗體媒介膜性腎病變之治療
CN118974082A (zh) 通过使用抗c5抗体可伐利单抗用于治疗或预防格林-巴利综合征的剂量及施用方案
US20250236661A1 (en) Dosage and administration regimen for the treatment or prevention of guillan-barre syndrome by the use of the anti-05 antibody crovalimab
JP2024517796A (ja) 抗ｂａｆｆｒ抗体を使用するループス腎炎の治療
WO2025096435A1 (en) Treatment of complement-associated renal diseases
CN118786147A (zh) 每月一次施用fviii模拟双特异性抗体的方法
WO2024112561A1 (en) Methods for the treatment of myasthenia gravis
HK40100364A (zh) 减少人类受试者中的tau的方法
JP2024516019A (ja) 抗ｂａｆｆｒ抗体を使用する全身性エリテマトーデスのための治療
CN116829582A (zh) 安全施用抗Tau抗体的方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination